Mostrar el registro sencillo del ítem

dc.contributor.authorGutiérrez Abejón, Eduardo
dc.contributor.authorCriado Espegel, Paloma
dc.contributor.authorHerrera Gómez, Francisco Magno
dc.contributor.authorÁlvarez González, Francisco Javier 
dc.date.accessioned2023-03-13T11:36:11Z
dc.date.available2023-03-13T11:36:11Z
dc.date.issued2020
dc.identifier.citationPharmaceuticals, 2020, Vol. 13, Nº. 8, 165es
dc.identifier.issn1424-8247es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/58918
dc.descriptionProducción Científicaes
dc.description.abstractInsulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study. Treatment duration with these medicines and the concomitant use of other DIMs were observed. An adjustment method was used with information from the drivers’ license census. For all calculations, age and gender were taken into account. 3.98% of the general population used at least one antidiabetic, as well as 2.92% of drivers. The consumption of antidiabetics in men was higher than in women (4.35% vs. 3.61%, p = 0.001), and the use increases with age, especially from 35–39 years to 75–79 years in men and 85–89 years in women. Antidiabetics were consumed chronically, specifically 100% in the case of insulins and 95% in the case of oral antidiabetics. In addition to antidiabetics, 2.5 ± 1.86 DIMs were consumed, mainly anxiolytics (25.53%), opioids (23.03%), other analgesics and antipiretics (19.13%), and antidepressants (17.73%). Collaboration between pharmacists and physicians is a priority to clearly transmitting risks to patients. It is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDiabeteses
dc.subjectDiabetes mellituses
dc.subjectInsulines
dc.subjectMedicamentos - Efectos fisiológicoses
dc.subjectDiabetes - Tratamientoes
dc.subjectAutomoviles - Conducciónes
dc.subjectDrugged driving - OECD countrieses
dc.titlePopulation-based registry analysis of antidiabetics dispensations: trend use in Spain between 2015 and 2018 with reference to drivinges
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2020 The Authorses
dc.identifier.doi10.3390/ph13080165es
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/13/8/165es
dc.identifier.publicationfirstpage165es
dc.identifier.publicationissue8es
dc.identifier.publicationtitlePharmaceuticalses
dc.identifier.publicationvolume13es
dc.peerreviewedSIes
dc.description.projectInstituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional (RD16/0017/0006)es
dc.identifier.essn1424-8247es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3209 Farmacologíaes


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem